Lung Cancer | Clinical

July 23, 2021

Ronald J. Scheff, MD, reviews the molecular testing practices for non–small cell lung cancer and frontline treatment of patients with PD-L1-positive non–small cell lung cancer during a Case-Based Roundtable event.

July 21, 2021

Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival versus supportive care in patients with PD-L1–positive non–small cell lung cancer.

July 20, 2021

Eric Nadler, MD, MPP, discusses the real-world impact of the IMpower133 trial on the efficacy of immunotherapy combination treatment in extensive-stage small cell lung cancer.

July 19, 2021

During a Targeted Oncology Case-Based Roundtable event, Balazs Halmos, MD, MS, discussed the case of a 73-year-old patient with early-stage small cell lung cancer.

July 19, 2021

In 2017, the American Society of Clinical Oncology and the Ontario Health-Cancer Care Ontario's non–small cell lung cancer expert panel published a guideline with recommendations for systemic therapy for patients with stage IV NSCLC.

July 18, 2021

Targeted Therapies in Oncology spoke with Martin J. Edelman, MD, do uncover what is next for small cell lung cancer after PD-1 inhibitor indication have been withdrawn.

July 08, 2021

Eric Nadler, MD, MPP, lead a Cased-Based Roundtable event during which participants discussed how PD-L1 expression in patient with non–small cell lung cancer impacts treatment decisions.

July 06, 2021

During a Targeted Oncology Case-Based Roundtable event, Catherine Shu, MD, moderated a discussion around the case of a 77-year-old patients with non–small cell lung cancer.

July 02, 2021

During a Targeted Oncology Case-Based Roundtable event, Jessica Bauman, MD, discussed the case of 59-year-old patient with RET-mutated non–small cell lung cancer.

June 28, 2021

Ticiana Leal, MD, explained her approach to treating a patient with extensive-stage small cell lung cancer, during a Targeted Oncology Case-Based Roundtable event.